Recce Pharmaceuticals achieves significant clinical trial milestone

Recce Pharmaceuticals (ASX:RCE) is progressing in its Phase II clinical trial for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) with RECCE® 327 Topical Gel (R327G). The trial has successfully dosed 20 out of 30 patients, all of whom have met primary endpoints with either a complete cure or notable improvement. The trial is anticipated to be completed by the end of 2024.

Recce Pharmaceuticals' strategic advancement and market potential

Recce Pharmaceuticals is nearing the completion of its Phase II clinical trial for R327G, targeting ABSSSI, with 20 out of 30 patients showing positive results. The trial is on track for completion in 2024. Interim results show all patients achieved significant improvement without any serious adverse events. The ABSSSI market is projected to grow substantially, with R327G positioned as a promising candidate. Recce Pharmaceuticals is dedicated to developing innovative anti-infectives, with a pipeline including RECCE® 327 (intravenous and topical), RECCE® 435 (oral therapy), and RECCE 529 (for viral infections). The company is recognized by the WHO and the FDA, with regulatory support enhancing its growth prospects. Recce owns its manufacturing capabilities, reinforcing its commitment to addressing unmet medical needs.

Recce Pharmaceuticals' executive insights on clinical progress

Interim data indicates a strong therapeutic response with no serious adverse events reported. This progress underlines the potential impact of R327G in treating complex bacterial infections, including diabetic foot infections.